IBO Stock Overview
A life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Universal Ibogaine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.03 |
| 52 Week Low | CA$0.005 |
| Beta | 6.95 |
| 1 Month Change | 0% |
| 3 Month Change | 150.00% |
| 1 Year Change | 0% |
| 3 Year Change | -68.75% |
| 5 Year Change | n/a |
| Change since IPO | -86.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBO | CA Healthcare | CA Market | |
|---|---|---|---|
| 7D | 0% | -2.8% | -0.8% |
| 1Y | 0% | 23.4% | 9.9% |
Return vs Industry: IBO underperformed the Canadian Healthcare industry which returned 23.4% over the past year.
Return vs Market: IBO underperformed the Canadian Market which returned 9.9% over the past year.
Price Volatility
| IBO volatility | |
|---|---|
| IBO Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.3% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 3.3% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine IBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nick Karos | universalibogaine.com |
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is headquartered in Calgary, Canada.
Universal Ibogaine Inc. Fundamentals Summary
| IBO fundamental statistics | |
|---|---|
| Market cap | CA$7.72m |
| Earnings (TTM) | -CA$2.05m |
| Revenue (TTM) | CA$2.33m |
3.3x
P/S Ratio-3.8x
P/E RatioIs IBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBO income statement (TTM) | |
|---|---|
| Revenue | CA$2.33m |
| Cost of Revenue | CA$1.78m |
| Gross Profit | CA$551.66k |
| Other Expenses | CA$2.60m |
| Earnings | -CA$2.05m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0066 |
| Gross Margin | 23.67% |
| Net Profit Margin | -88.01% |
| Debt/Equity Ratio | 259.9% |
How did IBO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 07:27 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Universal Ibogaine Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.